Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106) Meeting Abstract


Authors: Richardson, P. G.; Oriol, A.; Larocca, A.; Otero, P. R.; Moreb, J.; Blade, J.; Hassoun, H.; Cavo, M.; Alegre, A.; Mazumder, A.; Maisel, C.; Paner, A.; Leleu, X.; Zonder, J. A.; Harmenberg, J.; Thuresson, S.; Zubair, H.; Mateos, M. V.
Abstract Title: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
Meeting Title: 110th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title: Cancer Research
Volume: 79
Issue: 13 Suppl.
Meeting Dates: 2019 Mar 29-Apr 3
Meeting Location: Atlanta, GA
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2019-07-01
Language: English
ACCESSION: WOS:000488129900138
DOI: 10.1158/1538-7445.Am2019-ct154
PROVIDER: wos
Notes: Meeting Abstract: CT154 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hani Hassoun
    329 Hassoun
Related MSK Work